Jubilant Organosys and Eli Lilly have extended drug discovery collaboration agreement for next five years as their four years old research collaboration has successfully delivered multiple discovery milestones and pre-clinical candidates. Jubilant and Lilly had entered into an initial discovery research collaboration in late 2005. Lilly will continue to own any compounds developed under the collaboration and will be responsible for worldwide commercialization. Under the terms of the new five years agreement Jubilant will receive research funding and success-based discovery and development milestones.
Shaym Bhartia, chairman & managing director, said, “We are pleased at the continued success of the collaboration and its ability to deliver the desired impact on Lilly's discovery portfolio efforts. We look forward to strengthening this partnership for better outcomes in pursuit of our endeavour to accelerate global drug discovery and development practice.”
Dr William Chin, senior vice president for discovery and clinical research for Lilly, said, “Our collaboration with Jubilant has resulted in the identification of promising pre-clinical candidates in important therapeutic areas. We look forward to continuing our joint efforts to discover and develop novel medicines for patients.”
Mosur, CEO & president of global drug discovery and development at Jubilant, said, “The extension with Lilly is a testimony of collaborative efforts of scientists at Lilly and Jubilant and demonstrates the value of this pioneering effort in networked R&D and its true impact on global pharmaceutical industry. We also appreciate Lilly's guidance and support to the partnership and Jubilant's aspiration to become India's most innovative pharmaceutical research and development company accelerating drug development and enabling affordable patient care worldwide.”